DNMT3A and heart failure: To further investigate the impact of harboring DNMT3A CHIP-driver mutations on diffuse cardiac fibrosis in humans, we determined cardiac fibrosis using cardiac magnetic resonance imaging with myocardial mapping36–38 in patients with heart failure (Fig. 5a, Supplementary Table 2).